TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Genetic Risk and Health Coaching for Type 2 Diabetes and Coronary Heart Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 65 years~* Willingness and ability to provide informed consent~* Have an active email address and internet access~* Physical exam in the last 12 months with the following documented evaluations in EMR (Electronic Medical record):~  1. Blood pressure~ 2. Height and weight~ 3. Fasting blood glucose or Hemoglobin A1C (HbA1c)~ 4. Lipid panel (TC, LDL, HDL, TRIG) with at least one of them outside of the normal ranges defined as:~  i.BMI ≥ 25 kg/m2 (BMI = weight \[kg\] / ht \[m\]2)~ii.FPG \> 100 AND ≤ 125 mg/dL~iii.HbA1c \> 5.7% ≤ 6.4%~iv.SBP ≥ 130 mmHg~v.TC ≥ 200 mg/dL~vi.TRIG ≥ 150 mg/dL~vii.LDL ≥ 129 mg/dL~Exclusion Criteria:~* Projected deployment in the upcoming 6 months~* Diagnosed type 2 diabetes~* Diagnosed coronary heart disease (CHD) -(Myocardial Infarction, or documented CHD)~* Inability to ambulate or participate in physical activity~* Serious chronic disease related complications or conditions that could significantly affect study outcomes \[currently treated cancer, renal failure, cardiovascular accident (CVA) with residual effects on functioning~* Current participation in another research study~* Spouse, partner or other household member already participating in this study protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Standard Risk Assessment (SRA) (Type: ACTIVE_COMPARATOR): Subjects will receive a standard risk assessment only for coronary heart disease (CHD) and type 2 diabetes (T2D). Standard risk factors are reviewed by a provider at a risk counseling visit with the subject.
- SRA plus Health Coaching (HC) (Type: EXPERIMENTAL): In addition to the standard risk assessment for CHD and T2D subjects will receive health coaching intervention for 6 months
- SRA plus Genetic Risk Counseling (GRC) (Type: EXPERIMENTAL): In addition to the SRA subjects will receive genetic risk counseling at the risk counseling visit with a clinic provider. Genetic test results for CHD (rs10757274) and T2D (rs7903146, rs1801282, rs5219) risk variants will be incorporated into the risk profile reviewed with subjects.
- SRA+HC+GRC (Type: EXPERIMENTAL): In addition to the standard risk assessment for CHD and T2D subjects will receive genetic risk counseling and health coaching intervention for 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adhesion Performance Study of Lidocaine Topical System 1.8% Compared to Generic Lidocaine Patch 5% in Healthy, Adult, Human Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Must be healthy based on by medical history, laboratory work, ECG, and physical exam with BMI range between 18.00 and 30.00 kg/m2 inclusive.~* Be at least 18 years of age~* If childbearing potential, use of acceptable form of birth control~* In the case of females of childbearing potential, have a negative serum pregnancy test~Key Exclusion Criteria:~* Allergy or known hypersensitivity to lidocaine, amide-type local anesthetics, or any component of the product formulation~* Any major medical illness 3 months prior or any significant history or ongoing chronic medical illness~* Subjects with conditions that might affect application of the product or its adhesive properties (including psoriasis, eczema, atopic dermatitis, damaged or irritated epidermal layer, and excessive hair or oil on the skin)~* History of addiction, abuse, and misuse of any drug~* Use of local anesthetics of antiarrhythmic drugs (such as tocainide or mexiletine) within 14 days prior to product application

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Lidocaine Patch (Sequence T1T2) (Type: EXPERIMENTAL): Subjects receive both lidocaine topical system 1.8% and the generic lidocaine patch 5%. The sequence in which they receive the lidocaine products is determined by random assignment. For subjects in Arm 1, lidocaine 1.8% topical systems are applied in Period 1, and the generic lidocaine 5% patches are applied in Period 2.
- Lidocaine Patch (Sequence T2T1) (Type: EXPERIMENTAL): Subjects receive both lidocaine topical system 1.8% and the generic lidocaine patch 5%. The sequence in which they receive the lidocaine products is determined by random assignment. For subjects in Arm 2, generic lidocaine 5% patches are applied in Period 1, and the lidocaine 1.8% topical systems are applied in Period 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With Pemphigus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age \>=18 and \<= 80years~* consent obtained from patient~* effective female contraceptive method for women in procreate age~* new case of pemphigus vulgaris (PV) or pemphigus foliaceus (PF)~Exclusion Criteria:~* pemphigus vulgaris (PV) or pemphigus foliaceus (PF) treated~* pregnant woman or nursing mother~* woman able to have a baby and without contraception during the clinical trial period~* age \< 18 or \> 80~* karnovsky \< 50%~* serious antecedents of allergy or anaphylactic reaction with human monoclonal antibody~* patient with depletion lymphocytic treatment in the next month~* unstable angina or ischemic heart disease~* cardiac insufficiency~* cardiac rhythm trouble uncontrolled~* positive HIV serology~* positive hepatitis B and / or C serology~* no consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Rituximab (Type: EXPERIMENTAL): None
- Corticotherapy (Type: ACTIVE_COMPARATOR): General Corticotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA~* Eligible for treatment with etanercept according to Summary of Product Characteristics (SmPC), and applicable local guidelines.~* Aged 18 years or more~* Willing and able to self-inject etanercept.~* Able to store test drug at 2-8oC.~* Negative serum ß-human chorionic gonadotropin (ß-HCG) pregnancy test at baseline (week 0) for all women of childbearing potential. Sexually active women of childbearing potential must use a medically acceptable form of contraception. Medically acceptable forms of contraception include oral contraceptives, injectable or implantable methods, intrauterine devices, or properly used barrier contraception. Sexually active men must agree to use a reliable form of contraception during the study.~* Capable of understanding and willing to provide signed and dated written voluntary informed consent before any protocol-specific procedures are performed.~Exclusion Criteria:~* Prior experience of biologics and anti-TNF treatment for their Psoriasis including etanercept.~* Sepsis or risk of sepsis.~* Current or recent infections, including chronic or localized.~* Latex sensitivity.~* Vaccination with live vaccine in last 4 weeks, or expected to require such vaccination during the course of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Arm 1: Enbrel 50 mg Prefilled Syringe
- 2 (Type: ACTIVE_COMPARATOR): Arm 2 Enbrel 50 mg Autoinjector

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Alefacept (Amevive) With or Without Narrowband UVB Treatment in Patients With Psoriasis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe plaque-type psoriasis;~* disease duration for more than 6 months~* PASI above 10.~Exclusion Criteria:~* age \< 18 years;~* pregnancy or lactation;~* presence of a dysplastic nevus syndrome;~* photosensitive skin disease;~* autoimmune disease;~* severe renal or hepatic disease;~* presence or history of malignant skin tumors;~* presence of antinuclear antibodies;~* history of previous treatments with arsenic, methotrexate, or x-rays;~* within the last 4 weeks before enrollment into the study, UVB or PUVA treatment, immunosuppressive/-modulating drugs (such as corticosteroids, cyclosporine, and biologics such as infliximab, etanercept or efalizumab).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* Has not received any previous treatment with any approved or investigational drug or drug regimen for the treatment of hepatitis C~* Male and female subjects, 18 to 70 years of age, inclusive~* Genotype 1, chronic hepatitis C with detectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)~* Screening laboratory values, tests, and physical exam within acceptable ranges~* Able and willing to follow contraception requirements~* Able to read and understand, and willing to sign the informed consent form and abide by the study restrictions~Exclusion Criteria~* Subject has any contraindications to Pegasys® or Copegus® therapy~* Evidence of hepatic decompensation in cirrhotic subjects~* History of organ transplant~* History of, or any current medical condition which could impact the safety of the subject in participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- PBO 12 Week+Peg-IFN-alfa-2a, RBV 48 Week (Type: PLACEBO_COMPARATOR): Placebo (PBO) matched to telaprevir 750 mg tablet thrice daily for 12 weeks in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) 180 microgram per week (mcg/week) subcutaneous injection and ribavirin (RBV) tablet orally twice daily at a dose of 1000 milligram per day (mg/day) for subjects weighing less than (\<) 75 kilogram (kg) and 1200 mg/day for subjects weighing greater than or equal to (\>=) 75 kg, for 48 weeks.
- Telaprevir 8 Week, PBO 4 Week+Peg-IFN-alfa-2a, RBV 24/48 Week (Type: EXPERIMENTAL): Telaprevir 750 mg tablet thrice daily for 8 weeks, then PBO matched to Telaprevir 750 mg tablet thrice daily for 4 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.
- Telaprevir 12 Week+Peg-IFN-alfa-2a, RBV 24/48 Week (Type: EXPERIMENTAL): Telaprevir 750 mg tablet thrice daily for 12 weeks in combination with Peg-IFN-alfa-2a 180 mcg/week subcutaneous injection and RBV tablet orally twice daily at a dose of 1000 mg/day for subjects weighing \<75 kg and 1200 mg/day for subjects weighing \>=75 kg, for 24 to 48 weeks depending on individual response to telaprevir treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of Xyrem® (Sodium Oxybate) to Treat Fibromyalgia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects, 18 years or older who meet the American College of Rheumatology (ACR) diagnostic criteria for fibromyalgia.~Exclusion Criteria:~* Subjects will be excluded if they have a history of rheumatic disease or other disorders that may compromise reliable representation of subjective symptoms.~* Any other condition that will cause a risk to subjects if they participate in the trial is also a reason for exclusion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy of Prolonged-Release Melatonin Versus Placebo in Diabetic Patients Suffering From Insomnia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diabetic patients with proven presence of the disease who complained of insomnia.~Exclusion Criteria:~* Patients with liver or renal problems (serum creatinine above 1.5 mg/dL).

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo First (Type: OTHER): Subjects were treated for 3 weeks with 1 tablet per night of Placebo and then with 2 mg melatonin (Circadin).
- Circadin first (Type: OTHER): Subjects were treated for 3 weeks with 1 tablet per night of 2 mg melatonin (Circadin) and then with placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CBT Group for Adolescents With ADHD: a Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV ADHD diagnosis~* age between 15 and 21 years~* stabilized doses of medication for ADHD for at least 2 months prior to the study~* agreement not to seek out any other psychiatric or psychological treatment during the study.~Exclusion Criteria:~* affective disorders~* anxiety disorders~* psychotic disorders~* personality disorders~* substance use disorders in the past 6 months~* pervasive developmental disorder~* patients with an IQ lower than 85~* patients receiving concurrent psychological interventions.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- CBT group (Type: EXPERIMENTAL): This group consist on a combined intervention: CBT group + psychopharmacological treatment. The group program was based on cognitive-behavioral principles and also motivational interviewing techniques to facilitate skills implementation. The treatment comprised 12 manualized sessions with an inattention module and an impulsivity module.
- Psychopharmacological treatment (Type: ACTIVE_COMPARATOR): Participants were only visited to monitor their adherence and continuation on medications for ADHD (methylphenidate or atomoxetine) as prescribed by their psychiatrist.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Real-time fMRI and Neurofeedback of Brain Networks Mediating Trauma Memory Recall in PTSD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* Aged 21-50~* Medically healthy~Exclusion Criteria:~* Claustrophobia, or the inability to lie still in a confined space~* Major medical disorders (e.g., HIV, cancer)~* Magnetic metallic implants (such as screws, pins, shrapnel remnants, aneurysm clips, artificial heart valves, inner ear (cochlear) implants, artificial joints, and vascular stents)~* Electronic or magnetic implants, such as pacemakers~* Permanent makeup or tattoos with metallic dyes~* Currently pregnant~* A self-reported history of loss of consciousness (greater than 10 minutes)~* Physical disabilities that prohibit task performance (such as blindness or deafness)~* Psychotic disorders (e.g., schizophrenia)~* Any other condition that the investigator believes might put the participant at risk

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Healthy Participants (Type: EXPERIMENTAL): A group of healthy participants will be enrolled first in the pilot phase of the study. This phase allows for the refinement (prior to the implementing in our PTSD participant group) the application of our support vector machine based real-time functional magnetic resonance imaging (rt-fMRI) algorithm, which evaluates brain networks thought to mediate emotional arousal and presents them (in real time) to subjects to aide in volitional manipulation of arousal.
- PTSD Participants (Type: EXPERIMENTAL): A group of participants with symptoms of PTSD will be enrolled in the implementation phase of the study. This phase allows for the evaluation of rt-fMRI guidance of brain networks thought to mediate emotional arousal, specifically whether participants can learn volitional control of these networks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nasal Inhalation of Tobramycin in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Colonization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* subject has a confirmed diagnosis of cystic fibrosis~* detection of P. aeruginosa in nasal lavage (culture) with chronic P.a. colonization of the lung (from day -28)~* informed consent of the patients or parents~* subject is older than 7 years~* subject is able to comply with the inhalation procedures and nasal lavage procedures scheduled in the protocol~* women of childbearing potential are only included into the study, if they are using an effective method of birth control during the protocol~Exclusion Criteria:~* subject has a critical condition defined as: FEV1 \< 30% and / or SaO2 \< 93% without O2-substitution; need of O2-substitution~* subject had an ENT surgery within 3 months prior to study~* subject shows signs of nasal bleeding~* subject has an ear drum perforation~* subject had an acute rhinosinusitis or a pulmonary exacerbation at study entry with need of additional systemic antibiotic therapy against pseudomonas aerug.~* subject is unlikely to comply with the procedures scheduled in the protocol~* subject has a known allergic reaction to the medication~* subject is pregnant or breastfeeding~* subject participates in another clinical trial within 30 days prior to study entry or 30 days after end of the study.~* systemic (oral or intravenous) antibiotic treatment against P.a. 14 days prior to the inclusion and during the study~* if serum level of tobramycin is above 2 mg/l one hour after inhalation, subject has to withdraw the participation in the study.~* progressed renal insufficiency~* severe damage of the N. acusticus~* dizziness (potential damage of. N. vestibularis)

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tobramycin 80 mg (Type: ACTIVE_COMPARATOR): applied once daily via Pari Sinus nebulizer
- isotonic saline (Type: PLACEBO_COMPARATOR): applied once daily via Pari Sinus nebulizer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients meeting the Rome III Diagnostic Criteria~* Loose (mushy) or watery stools within the last 3 months~Exclusion Criteria:~* Patients with a history of surgical resection of the stomach, small intestine or large intestine~* Patients with a history or current diagnosis of inflammatory bowel disease (Crohn's disease or colitis ulcerative)~* Patients with a history or current diagnosis of colitis ischemic~* Patients with a current diagnosis of enteritis infectious~* Patients with a current diagnosis of hyperthyroidism or hypothyroidism~* Patients who are currently participating in another clinical trial (including a post-marketing clinical study) or those who participated in another clinical trial (including a post-marketing clinical study) within 12 weeks before the study~* Patients with a history or current diagnosis of malignant tumor~* Patients with a history of abuse of drugs or alcohol within 1 year or those who are currently abusing them

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- ramosetron group (Type: EXPERIMENTAL): None
- Placebo group (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete